Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12388288 | 0.81 | GGPS1 (0.38) | GGPS1PTGS2 | |
| SCHEMBL25416535 | 0.72 | — | — | |
| SCHEMBL5656543 | 0.71 | GGPS1 (0.36) | GGPS1HSD11B1PTGS2 | |
| SCHEMBL31624291 | 0.70 | MAPT (0.42) | — | |
| SCHEMBL12364133 | 0.69 | ALDH1A1 (0.36) | — | |
| SCHEMBL16815632 | 0.69 | CYP17A1 (0.35) | — | |
| SCHEMBL3740763 | 0.69 | PTGS2 (0.59) | HSD11B1PTGS2 | |
| SCHEMBL4195851 | 0.68 | HSD11B1 (0.61) | HSD11B1 | |
| SCHEMBL16815645 | 0.68 | GGPS1 (0.40) | GGPS1HSD11B1PTGS2 | |
| SCHEMBL25415169 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA AS (DK) | 2025-06-19 | — | — | US | disclosed |
| EP-4486737-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO Pharma A/S (DK) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166172-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166172-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197378-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | GGPS1 2486/4885HSD11B1 653/4885PTGS2 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.